Moderna

ACIP recommended 2024–2025 COVID-19 vaccination with FDA-approved vaccines for all persons aged ≥6 months, targeting currently circulating SARS-CoV-2 strains, including Omicron JN.1 lineage (JN.1 and KP.2), to provide additional protection against severe COVID-19–associated illness and death.

China's first independently developed mpox vaccine approved for human trials by National Medical Products Administration, potentially aiding in disease control. The vaccine, developed by Shanghai Institute of Biological Products, uses Modified Vaccinia Ankara strain technology similar to Bavarian Nordic's Jynneos. China has not yet approved any mpox vaccines for marketing, with only a few smallpox-adapted vaccines available in some countries.

The global mRNA vaccine market is projected to decline at a CAGR of -4.3% from 2024 to 2034, reaching US$ 9.6 billion by 2034. Factors driving market growth include streamlined approval processes, innovations in logistics, increasing public trust, and ongoing research into long-term efficacy. Key players include Pfizer-BioNTech, Moderna, and Novartis, with North America leading in market share.

CoherentMI's report on the RNA Therapeutics Market projects it to grow from US$2.5M in 2024 to US$948M by 2031, at a CAGR of 68%. The market leverages RNA interference and antisense technologies for gene expression modulation, targeting hereditary disorders, cancer, and infectious diseases. Key players include Alphavax, Arcturus Therapeutics, Atyr Pharma, and Gritstone Bio. The market is driven by increasing R&D investments and demand for precision medicine.

Moderna's Laval, Quebec facility granted Drug Establishment License by Health Canada, enabling mRNA vaccine production in Canada by 2025, including COVID-19, RSV, and seasonal influenza vaccines.

Newly updated COVID-19 vaccines, including mRNA vaccines from Moderna and Pfizer-BioNTech and the Novavax protein-based vaccine, are available across the U.S. The CDC recommends everyone age 6 months and older receive the updated vaccine, which targets the KP.2 strain of COVID-19. Vaccines offer protection against severe illness, hospitalization, and death, and help prevent long COVID. Individuals at higher risk, such as the elderly and immunocompromised, should get vaccinated promptly. The vaccine is free for those with insurance and through certain programs for uninsured individuals and children.

Rosen Law Firm filed a class action lawsuit on behalf of Moderna, Inc. (NASDAQ: MRNA) securities purchasers between January 18, 2023, and June 25, 2024. The lawsuit alleges false and misleading statements regarding mRNA-1345's effectiveness. Lead plaintiff deadline is October 8, 2024.

Lykos Therapeutics reshuffles senior management after FDA rejection of MDMA-AT for PTSD, appointing Michael Mullette as interim CEO and Dr. David Hough as CMO. The company focuses on regulatory engagement and clinical development, with Mullette and Hough bringing extensive pharma experience. Amy Emerson steps down as CEO, transitioning to an advisory role, marking Lykos' shift from its MAPS roots towards medicalizing MDMA.

ArtLifting, founded by Liz and Spencer Powers, brokers art by disadvantaged artists, earning them $6.5 million. Their works, including by Allen Chamberland and Lisa Murphy, are displayed in corporate offices, including Moderna and Foundation Medicine, aiming to break stigmas and provide income.